Sugi Predict

Sugi Predict / Compounds / SCHEMBL30214730

SCHEMBL30214730

SCHEMBL30214730

COC(=O)[C@@H]1C[C@H](OS(C)(=O)=O)CN1C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 9/20 0.45
▸ ANPEP P15144 3/20 0.45
▸ CYP19A1 P11511 1/20 0.39
▸ KMT2A Q03164 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ KCNN4 O15554 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29276109 1.00 MMP2 (0.45) MMP2ANPEPCYP19A1KMT2AALDH1A1
SCHEMBL29276107 1.00 MMP2 (0.45) MMP2ANPEPCYP19A1KMT2AALDH1A1
SCHEMBL25368522 0.89 MMP2 (0.36) MMP2ANPEP
SCHEMBL3832522 0.86 MMP2 (0.41) MMP2ANPEPKMT2AHSD17B10KCNN4
SCHEMBL6586331 0.86 MMP2 (0.41) MMP2ANPEPKMT2AHSD17B10KCNN4
SCHEMBL5202136 0.85 MMP2 (0.40) MMP2ANPEPKMT2AHSD17B10KCNN4
SCHEMBL3544176 0.85 MMP2 (0.40) MMP2ANPEPKMT2AHSD17B10KCNN4
SCHEMBL5200976 0.82 MMP2 (0.41) MMP2ANPEPKMT2AALDH1A1KCNN4
SCHEMBL29276034 0.82 MMP2 (0.41) MMP2ANPEPKMT2AALDH1A1KCNN4
SCHEMBL3548773 0.82 MMP2 (0.41) MMP2ANPEPKMT2AALDH1A1KCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658654-A1 PYRROLO[1,2-D][1,2,4]TRIAZINES AND PYRAZOLO[1,5-D] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS Janssen Pharmaceutica NV (BE) 2025-12-10 — — EP disclosed
EP-4658653-A1 IMIDAZO[1,2-D][1,2,4]TRIAZINES AS NLRP3 INHIBITORS Janssen Pharmaceutica NV (BE) 2025-12-10 — — EP disclosed
CN-119212699-A NLRP3 inhibitors PTC医疗公司 2024-12-27 — — CN disclosed
EP-4479045-A2 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-12-25 — — EP disclosed
WO-2024160691-A1 PYRROLO[1,2-d][1,2,4]TRIAZINES AND PYRAZOLO[1,5-d] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-08-08 — — WO disclosed
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 — — US disclosed
WO-2024160692-A1 IMIDAZO[1,2-D][1,2,4]TRIAZINES AS NLRP3 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-08-08 — — WO disclosed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 — — CN disclosed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
WO-2023159148-A2 INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023028534-A1 INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2023-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262806-A1 INHIBITORS OF NLRP3 NLRP3, NOD1, NLRP1 MMP2 2118/4885ANPEP 2796/4885CYP19A1 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.